New specialist European and US life sciences investors join existing investors to enable Nouscom to continue advancing the clinical development of its.
Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic Use of proceeds will enable the development of the Company's lead autoimmune program DT-001, targeting
EQS-News: Andera Partners / Key word(s): Financing Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases 15.05.2023
New investors, Andera Partners and Earlybird Venture Capital, join existing investor, Pureos Bioventures raising an additional EUR 22.75 million Funds will be used to advance clinical